Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mallinckrodt Splurges Up To $410m On Three Hemostasis Drugs

This article was originally published in Scrip

Executive Summary

Mallinckrodt PLC is buying three commercial-stage topical hemostasis drugs – Recothrom Thrombin topical (recombinant), PreveLeak Surgical Sealant, and Raplixa (Fibrin Sealant) from The Medicines Company for an initial payment of $175m that includes existing inventory. However, the value of the deal could rise by $235m subject to future milestone payments and the total could reach up to $410m.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts